This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Weibiao Han
Introduction
Weibiao Han is a notable inventor based in Chengdu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of compounds aimed at treating viral diseases. His work exemplifies the intersection of innovation and practical application in medicine.
Latest Patents
Weibiao Han holds a patent for a solid form of a dihydropyrimidine compound, along with its preparation method and uses. The patent, titled "Solid form of dihydropyrimidine compound and preparation method therefor and use thereof," discloses a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid. This invention includes a preparation method, a pharmaceutical composition, and its application in the development of drugs for preventing or treating viral diseases. He has 1 patent to his name.
Career Highlights
Weibiao Han is currently employed at Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. His role at the company allows him to leverage his expertise in biopharmaceutical innovation. His contributions have been instrumental in advancing the company's research and development efforts.
Collaborations
Weibiao has collaborated with several talented individuals in his field, including Tianming Wang and Chengxi Yang. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their research projects.
Conclusion
Weibiao Han's work in the biopharmaceutical sector highlights the importance of innovation in developing effective treatments for viral diseases. His patent and collaborations reflect a commitment to advancing medical science and improving patient outcomes.